ARTICLE | Company News
GeneMedicine other research news
October 17, 1994 7:00 AM UTC
The Houston company received an $81,000 Phase I SBIR from the National Institute of Diabetes and Digestive and Kidney Diseases to develop synthetic muscle-specific gene expression systems to provide high levels of cell-specific gene expression in gene therapies. ...